Elizabeth Seaquist, MD
Elizabeth Seaquist, MD, is a diabetes expert whose ultimate goal is to improve the lives of people with diabetes. Seaquist’s research interests looks at the effects of diabetes on brain metabolism, structure and function. She is currently heading projects to learn how the brain adapts to diabetes and recurrent hypoglycemia with the long term goal of developing new therapies for the disease. She also leads the NIH funded ACCORDION (Action to control cardiovascular risk in diabetes follow on study), the Eli Lilly funded Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) study, and is principal investigator on the NIH funded T32 training grant in diabetes, endocrinology, and metabolism. Currently, Seaquist is leading the University of Minnesota site for glycemia reduction approaches in diabetes (GRADE), which are NIH and clinically funded trials focused on identifying the best treatments for patients with type 2 diabetes.